Table 2.
Association between the clinicopathological features and immunostaning score of HMGB1 in 66 recurrent CSCC and 70 non-recurrent CSCC paraffin block tissues*
| Characteristics | HMGB1 (%) |
P† | |
|---|---|---|---|
| low expression number | high expression number | ||
| Age (years): | 0.736 | ||
| ≤45 (n = 59) | 25 (42.4) | 34 (57.6) | |
| >45 (n = 77) | 31 (40.3) | 46 (59.7) | |
| FIGO stage: | 0.012 | ||
| I-II (n = 85) | 43 (50.6) | 42 (49.4) | |
| III-IV (n = 51) | 13 (25.5) | 38 (74.5) | |
| Differentiation grades: | 0.146 | ||
| well/ moderately differentiated (n = 102) | 43 (42.2) | 59 (57.8) | |
| poorly differentiated (n = 34) | 13 (38.2) | 21 (61.8) | |
| Relapse: | 0.008 | ||
| yes (n = 66) | 19 (28.8) | 47 (71.2) | |
| no (n = 70) | 37 (52.9) | 33 (47.1) | |
| Lymph node metastases: | 0.028 | ||
| yes (n = 71) | 26 (32.4) | 45 (67.6) | |
| no (n = 65) | 30 (46.2) | 35 (53.8) | |
| Distant metastasis | <0.001 | ||
| yes (n = 22) | 4 (18.2) | 18 (81.8) | |
| no (n = 114) | 52 (45.6) | 62 (54.4) | |
*Abbreviations: HMGB1 – high mobility group box chromosomal protein 1; CSCC – cervical squamous cell carcinoma; FIGO – International Federation of Gynecology and Obstetrics (16).
†Pearson χ2 test.